Lisata Therapeutics, Inc. (LSTA)
(Delayed Data from NSDQ)
$3.43 USD
-0.24 (-6.59%)
Updated Jun 12, 2024 03:56 PM ET
After-Market: $3.59 +0.16 (4.73%) 7:58 PM ET
4-Sell of 5 4
D Value F Growth B Momentum F VGM
Price, Consensus and EPS Surprise
LSTA 3.43 -0.24(-6.59%)
Will LSTA be a Portfolio Killer in June?
Zacks Investment Research is releasing its prediction for LSTA based on the 1-3 month trading system that more than doubles the S&P 500.
About Price, Consensus and EPS Surprise
The Price, Consensus and EPS Surprise chart displays the company's stock price along with the consensus estimate and the EPS surprise. Zacks tracks individual sell-side analyst estimates and creates a consensus EPS estimates. The consensus estimate is the average of all the current estimates made available by brokerage analysts. Consensus estimates are more advantageous because they reduce the risk of any single analyst making an incorrect forecast. ZACKS CONSENSUS ESTIMATE = THE AVERAGE OF ALL CURRENT EPS ESTIMATES. EPS Surprise is the difference (expressed as a percentage) between the actual reported quarterly earnings per share (EPS) vs the estimated quarterly EPS. A company that reports $1.10 in actual quarterly EPS vs. $1.00 in estimated quarterly EPS would show a 10% positive EPS surprise. ((Actual EPS - Estimated EPS) / absolute Estimated EPS) *100 = EPS Surprise %.
Zacks News for LSTA
Lisata's (LSTA) LSTA1 Gets FDA Orphan Drug Tag for Osteosarcoma
Lisata's (LSTA) LSTA1 Gets FDA's RPDD Tag for Osteosarcoma
LSTA: What are Zacks experts saying now?
Zacks Private Portfolio Services
Lisata (LSTA) Stock Up More Than 35% in 3 Months: Here's Why
All You Need to Know About Lisata Therapeutics, Inc. (LSTA) Rating Upgrade to Buy
Lisata's (LSTA) Lead Cancer Drug Gets EC's Orphan Tag, Stock Up
Other News for LSTA
Lisata Therapeutics to Participate in Upcoming June 2024 Industry and Investor Events
Buy Rating on Lisata Therapeutics Backed by Regulatory Milestones and Promising Study Progress
Lisata Therapeutics Receives Paediatric Investigation Plan Waiver from the European Medicines Agency for Certepetide in Pancreatic Cancer
Lisata Therapeutics receives PIP waiver from EMA for certepetide
Positive Outlook for Lisata Therapeutics as Analyst Reaffirms Buy Rating Amid Strong Financials and Promising Clinical Trials